<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632915</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00066222</org_study_id>
    <nct_id>NCT03632915</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Antiepileptics in Patients on CRRT</brief_title>
  <acronym>PADRE</acronym>
  <official_title>Pharmacokinetics of Antiepileptic Drugs in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Translational Medicine (CTM), University of Maryland School of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to measure levels of any of the following AEDs (levetiracetam,
      phenobarbital, phenytoin, ketamine, valproic acid, lacosamide) in blood and effluent on
      critically ill patients receiving CRRT in order to characterize drug pharmacokinetics and
      optimize dosing strategies in patients on CRRT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of renal replacement therapy on drug exposure (AUC of plasma concentration levels)</measure>
    <time_frame>Single Dosing Interval - 12 hours</time_frame>
    <description>Simultaneous samples will be taken from pre-filter, post-filter, and effluent sampling ports before dose administration, after the completion of the infusion or 1 hours post oral dose, and 6 additional time points post-infusion or post oral administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of renal replacement therapy on drug clearance</measure>
    <time_frame>Single Dosing Interval - 12 hours</time_frame>
    <description>Simultaneous samples will be taken from pre-filter, post-filter, and effluent sampling ports before dose administration, after the completion of the infusion or 1 hours post oral dose, and 6 additional time points post-infusion or post oral administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of drug specific sieving coefficient (SC)</measure>
    <time_frame>Single Dosing Interval - 12 hours</time_frame>
    <description>SC is a measure of a filter efficiency in clearing drugs and solute. SC will be calculated using pre-filter and effluent concentrations</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Renal Failure</condition>
  <condition>Pharmacokinetics</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin</intervention_name>
    <description>Standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenobarbital</intervention_name>
    <description>Standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Standard of care</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Expected to be on CRRT and receive any of the following for more than 24 hrs

          -  Expected to survive for more than 24 hrs

          -  Achievement of steady state drug concentrations prior to study enrollment

        Exclusion Criteria:

          -  Pregnancy

          -  Age &lt; 18

          -  Prisoner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeraj Badjatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shamir N Kalaria, Pharm.D.</last_name>
    <phone>4107061480</phone>
    <email>skalaria@umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Armahizer, Pharm.D.</last_name>
    <phone>4106285644</phone>
    <email>michaelarmahizer@umm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shamir N. Kalaria, Pharm.D.</last_name>
      <phone>410-628-5644</phone>
      <email>shamir.kalaria@umm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Neeraj Badjatia</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Antiepileptics</keyword>
  <keyword>Continuous Renal Replacement Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

